Patents by Inventor Patricia Rockwell

Patricia Rockwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
    Publication number: 20090022714
    Abstract: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGFR antagonist and an EGFR antagonist.
    Type: Application
    Filed: October 20, 2006
    Publication date: January 22, 2009
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • COMBINATION METHODS OF INHIBITING TUMOR GROWTH WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTAGONIST
    Publication number: 20090022716
    Abstract: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.
    Type: Application
    Filed: July 25, 2007
    Publication date: January 22, 2009
    Applicant: IMCLONE SYSTEMS INC.
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Monoclonal antibodies specific to VEGF receptors and uses thereof
    Publication number: 20050004066
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Application
    Filed: July 28, 2004
    Publication date: January 6, 2005
    Inventors: Patricia Rockwell, Neil Goldstein
  • Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
    Patent number: 6811779
    Abstract: The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: November 2, 2004
    Assignee: ImClone Systems Incorporated
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
    Publication number: 20030108545
    Abstract: The present invention provides a method of reducing or inhibiting tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation, chemotherapy, and/or an additional receptor antagonist.
    Type: Application
    Filed: March 4, 2002
    Publication date: June 12, 2003
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy
    Publication number: 20030103973
    Abstract: The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.
    Type: Application
    Filed: March 2, 2001
    Publication date: June 5, 2003
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Monoclonal antibodies specific to VEGF receptors and uses thereof
    Publication number: 20020192213
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Application
    Filed: March 4, 2002
    Publication date: December 19, 2002
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Chimeric and humanized monoclonal antibodies specific to VEGF receptors
    Patent number: 6448077
    Abstract: Chimeric and humanized monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: November 10, 1997
    Date of Patent: September 10, 2002
    Assignee: ImClone Systems, Inc.
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Monoclonal antibodies specific to VEGF receptors and uses thereof
    Patent number: 6365157
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: September 22, 1999
    Date of Patent: April 2, 2002
    Assignee: ImClone Systems, Inc.
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • MONOCLONAL ANTIBODIES SPECIFIC TO VEGF RECEPTORS AND USES THEREOF
    Publication number: 20020009750
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of flt-1 receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Application
    Filed: September 22, 1999
    Publication date: January 24, 2002
    Inventors: PATRICIA ROCKWELL, NEIL I. GOLDSTEIN
  • Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
    Patent number: 6030955
    Abstract: The present invention provides methods of stimulating or inhibiting intracellular phosphorylation of tyrosine by a heparin-binding receptor which comprises contacting a cell having on its surface the heparin-binding receptor with a phosphorothioate oligonucleotide moiety of suitable length and base composition, such phosphorothioate oligonucleotide moiety being present in an effective amount. The invention further provides a method of inhibiting the formation of blood vessels in a subject which comprises administering to the subject an amount of a phosphorothioate oligonucleotide moiety of suitable length and base composition. The invention also provides a method of inhibiting proliferation of cells having a malignant phenotype in a subject which comprises administering to the subject an amount of a phosphorothioate oligonucleotide moiety of suitable length and base composition.
    Type: Grant
    Filed: March 21, 1996
    Date of Patent: February 29, 2000
    Assignee: The Trustees of Columbia University in The City of New York and ImClone Systems, Inc.
    Inventors: Cy Stein, Patricia Rockwell
  • Monoclonal antibodies specific to VEGF receptors and uses thereof
    Patent number: 5955311
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: September 21, 1999
    Assignee: ImClone Systems Incorporated
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Single chain antibodies specific to VEGF receptors
    Patent number: 5874542
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: February 23, 1999
    Assignee: Imclone Systems Incorporated
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
    Patent number: 5861499
    Abstract: Nucleic acid molecules comprising a nucleic acid sequence that encodes an amino acid sequence wherein the amino acid sequence consists of the variable region or of the hypervariable region of a monoclonal antibody that specifically binds to an extracellular domain of a VEGF receptor and neutralizes activation of the receptor.
    Type: Grant
    Filed: September 3, 1996
    Date of Patent: January 19, 1999
    Assignee: ImClone Systems Incorporated
    Inventors: Patricia Rockwell, Neil I. Goldstein
  • Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
    Patent number: 5840301
    Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of a VEGF receptor and neutralize activation of the receptor are provided. In vitro and in vivo methods of using these antibodies are also provided.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: November 24, 1998
    Assignee: ImClone Systems Incorporated
    Inventors: Patricia Rockwell, Neil I. Goldstein